patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
janus kinase (JAK) inhibitor - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.67 [0.52, 0.87]< 1 43% 7 studies (7/-) 99.9 % low serious high crucial - death or transfer to ICU 0.93 [0.87, 0.99]< 1 0% 1 study (-/1) 98.6 % NA not evaluable crucial - deaths 0.60 [0.47, 0.78]< 1 46% 11 studies (9/2) 100.0 % low critical high crucial - deaths (time to event analysis only) 0.59 [0.45, 0.78]< 1 0% 2 studies (2/-) 100.0 % low not evaluable high crucial - clinical deterioration 0.78 [0.38, 1.60]< 1 56% 2 studies (2/-) 74.9 % low not evaluable high important - clinical improvement 1.22 [1.07, 1.39]> 1 10% 5 studies (5/-) 99.9 % low serious high important - clinical improvement (14-day) 1.31 [1.13, 1.52]> 1 0% 3 studies (3/-) 100.0 % low not evaluable high important - clinical improvement (28-day) 1.92 [0.96, 3.82]> 1 0% 3 studies (3/-) 96.8 % low not evaluable high important - clinical improvement (time to event analysis only) 1.16 [1.01, 1.33]> 1 0% 1 study (1/-) 98.5 % NA not evaluable important - death or ventilation 0.78 [0.62, 0.99]< 1 56% 3 studies (3/-) 98.1 % some concern not evaluable moderate important - hospital discharge 23.94 [10.77, 53.20]> 1 0% 1 study (-/1) 100.0 % NA not evaluable important - mechanical ventilation 0.72 [0.49, 1.06]< 1 49% 4 studies (4/-) 95.0 % some concern not evaluable moderate important - ICU admission 0.12 [0.03, 0.49]< 1 49% 2 studies (-/2) 99.8 % low not evaluable high non important - recovery 1.57 [0.77, 3.20]> 1 0% 1 study (1/-) 89.3 % NA not evaluable non important - safety endpoints 00 related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - superinfection 0.50 [0.32, 0.79]< 1 0% 1 study (1/-) 99.8 % NA not evaluable important - acute kidney injury 0.43 [0.14, 1.34]< 1 0% 1 study (-/1) 92.7 % NA not evaluable non important - adverse events 0.12 [0.01, 1.37]< 1 2% 2 studies (2/-) 95.5 % some concern not evaluable moderate non important - arrhythmia 0.16 [0.03, 0.90]< 1 0% 1 study (-/1) 98.1 % NA not evaluable non important - elevated liver enzymes 0.52 [0.18, 1.51]< 1 0% 1 study (-/1) 88.5 % NA not evaluable non important - Myocardial infarction 0.87 [0.19, 3.92]< 1 0% 1 study (-/1) 57.2 % NA not evaluable non important - venous thromboembolism 5.23 [0.42, 65.62]< 1 0% 1 study (-/1) 10.2 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.